Loading
  1. Legalization
  2. About Marijuana
  3. NORML Blog
  4. Lawyers
  5. Research
legal marijuanaLegalization has been adopted (either in part or in full) by voter initiatives in a number of US jurisdictions: Colorado (2012), Washington (2012), Alaska (2014), Oregon (2014), Washington, DC (2014), California (2016), Maine (2016), Massachusetts (2016), and Nevada (2016).

mj plantMarijuana is the third most popular recreational drug in America (behind only alcohol and tobacco), and has been used by nearly 100 million Americans. According to government surveys, some 25 million Americans have smoked marijuana in the past year, and more than 14 million do so regularly despite harsh laws against its use. Our public policies should reflect this reality, not deny it.
 
NORML Blog

Read the NORML Blog for the latest news in marijuana law reform »

nlc logoMarijuana prohibition causes far more problems than it solves, and results in the needless arrest of hundreds of thousands of otherwise law abiding citizens each year. The NORML Legal Committee provides legal support and assistance to victims of the current marijuana laws.
 
us map selectFor 40 years, NORML has served as a clearinghouse for marijuana-related information. Much of this information is now available online in NORML's Library.
 

NORML Blog, Marijuana Law Reform »

Working to reform marijuana laws
  • Read more by NORML

    One of NORML’s primary missions is to move public opinion sufficiently to legalize the responsible use of marijuana by adults. One of the ways we successfully achieve this goal is by debunking marijuana myths and half-truths via the publication of timely op-eds in online and print media. Since the mainstream media seldom casts a critical eye toward many of the more over-the-top claims about cannabis, we take it upon ourselves to set the record straight.

  • Read more by NORML

    Governor Phil Scott (R) vetoed S. 22 to all eliminate penalties for the possession and cultivation of personal use amounts of marijuana by July 2018.

  • Read more by Erik Altieri, NORML Executive Director

    If the latest comments and memos coming out of Attorney General Sessions' Department of Justice didn't raise concerns about the Trump Administration's potential plans to reignite our nation's failed war on drugs, his recent call with Philippines President Rodrigo Duterte should sound alarm bells.

  • Read more by Paul Armentano, NORML Deputy Director

    The Asbury Park Press and other Gannett newspaper affiliates published a fairly extensive online debate on Sunday between myself and Project SAM co-founder Kevin Sabet under the header "Should We Make Marijuana Legal?" Who wins the debate? You be the judge.

  • Read more by Chris Thompson, Executive Director, Las Vegas NORML

    Members of Las Vegas NORML focus on home cultivation, social consumption and protections for medical marijuana patients. Pending legislation would re-establishing patient cultivation rights, permit medical marijuana research facilities, and add PTSD as a qualifying condition for medical marijuana.

  • Read more by Justin Strekal, NORML Political Director

    This year, it seems that multiple states are vying for the honor of becoming the first state to legalize marijuana through the legislative process and four of them had movement this week. Following are the bills from around the country that we’ve tracked this week and as always, check http://norml.org/act for legislation pending in your state.

  • Read more by Erik Altieri, NORML Executive Director

    I think Quist’s opponents may be surprised by the reaction this “revelation” will evoke from most Montana residents, and Americans across the spectrum. That reaction can largely be summed up as: “So what?”

  • Read more by Paul Armentano, NORML Deputy Director

    Inhaled cannabis is effective and well-tolerated in patients with Tourette’s Syndrome, according to clinical data published online ahead of print in the Journal of Neuropsychiatry and Clinical Neuroscience. They concluded: “Overall, these study participants experienced substantial improvements in their symptoms. This is particularly striking given that almost all participants had failed at least one anti-tic medication trial.